CD19 and acquired idiopathic inflammatory myopathy: Autologous CD19 CAR-T-cell therapy has also demonstrated efficacy in inducing remission in 15 patients with refractory autoimmune diseases, including 8 with SLE, 3 with idiopathic inflammatory myositis (IIM), and 4 with SSc [10].